α-Synuclein-IN-24

α-Synuclein-IN-24 (Compound 2dc) (30 μM; 96 h) inhibits the aggregation of purified human α-synuclein at all stages of the entire aggregation process, reduces the aggregation rate constant to 0.107 h⁻¹, and when incubated at a concentration of 30 μM for 96 h, its main mechanism of action is to reduce the formation of oligomeric nuclei during the lag phase^[1].
α-Synuclein-IN-24 (30 μM; 88 h) reduces the formation of large, interconnected purified human α-synuclein fibrils, and incubation at 30 μM for 88 h produces shorter, sparser fibrils^[1].
α-Synuclein-IN-24 (30 μM; 0-88 h) effectively depolymerizes preformed purified human α-synuclein aggregates and inhibits their re-aggregation; when added at a concentration of 30 μM during the lag phase (21 h), it achieves the highest re-aggregation inhibition rate of up to 76.6%^[1].
α-Synuclein-IN-24 (10 μM; 48 h) inhibits the formation of α-synuclein (α-Syn) inclusions in plasmid-transfected human glioma H4 cells^[1].
α-Synuclein-IN-24 (3-10 μM; 30 min) dose-dependently scavenges reactive oxygen species (ROS) in human glioma H4 cells, and reduces ROS production to approximately 30% of that in the H₂O₂-treated control group at a concentration of 10 μM^[1].
α-Synuclein-IN-24 (1-100 μM; 24 h) exhibits cytotoxicity in human glioma H4 cells: the cell survival rate is < 85% at the concentration of 100 μM, whereas it shows a slight pro-proliferative effect after 24 h incubation at concentrations of 1-3 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.